APTO - Aptose Appoints Fletcher Payne Chief Business Officer Expanding his Executive Role | Benzinga
SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer.
With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO and senior management positions at biotech companies in addition to finance and accounting roles, and has overseen legal, corporate development and licensing functions. During his career, he has executed a wide array of business transactions totaling more than $3.7 billion, with healthcare focus in clinical testing, oncology, neurological, and orphan diseases indications.
"Fletcher's financial and business oversight has proven to be instrumental as we continue to evolve our business and operations strategies," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "He brings the strategic leadership necessary at a time of significant opportunity for Aptose."
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial ...